Search Results

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the market, as the drugmaker expects to submit the drug for approval for weight loss by the end of the year.

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and transparent analytics to ensure their pharmacy plan design aligns with their unique cost control and member health priorities.

Zepbound could add a quality-adjusted life year for $100,000 when the annual cost falls to $4,334.

With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely be key in determining the impact of GLP-1s on plan costs.

The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.

Nearly one-third of adult employees would change jobs in order to gain coverage.

North Dakota's rules for which patients get semaglutide and tirzepatide coverage may conflict with drug manufacturers' rebate strategies.